Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Post by Pareto8020on Jul 02, 2021 1:37pm
277 Views
Post# 33485045

Cafe Interview on milestones

Cafe Interview on milestonesThe Cafe Pharma interview included the below from SBM's fearless CEO.  That was from May 25th  and is posted on the Sirona website.  So if just over a month later they are revising milestones (again) Howard will have proved himself a liar once more and should be stepping down as CEO.  Otherwise stop blaming everyone except yourself and start closing some deals instead of adding new companies into the mix and just endlessly extending milestones.  Now is the time for some deals and revenue not dilution in whatever form Howard cooks it up.    

.....

Dr. Verrico, in your latest presentation for investors you listed milestones to be achieved within the next three months. To what extent are you still confident of achieving these milestones and where do you see the greatest impact for Sirona?

Dr. Verrico: I am confident we will be able to achieve most of our milestones and that Sirona will be launched into a new era. In terms of impact, there is one milestone we did not include and that was the first commercialization of our product TFC-1067. We intentionally left this off as the timeline was not ours and so hesitated to call it our milestone, however, having a product reach commercialization it certainly is a significant turning point for any biotech company.

The other impactful event will be any partnering agreement, whether this is for our SGLT2 product or a second TFC-1067 agreement.

<< Previous
Bullboard Posts
Next >>